English
|
Spanish
Supporting oncology professionals through education
Login
Register
The content on this site is intended for healthcare professionals only
Menu
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
News
Latest news
Sign up for news alerts
Submit your news
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Journal information
Journal home
Charges
Editorial board
Founding editors
Editor-in-chief
Contact us
Author information
Submit article
Author guidelines
Editorial policies
Copyright information
Why publish with us
Reviewer information
Reviewer guidelines
Memberships
Videos
Recent videos
Sign up
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Conferences
Latest conferences
Sign up for latest coverage
Submit your event
About
e
cancer
About
e
cancer
Our founders
Funding statement
Contact us
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+
-
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
ASH 2009: Novel agents for multiple myeloma
Share :
ASH 2009
3 Dec 2011
Please rate this video
The information in this video was of interest to me
The information in this video is likely to improve my clinical practice or research
I would recommend this video to my colleagues
Published:
1 Mar 2010
Views:
10113
Rating:
Save
Rate video
Dr Shaji Kumar - Hematology, Mayo Clinic, Rochester, USA
Dr Shaji Kumar discusses the improvement in treatment of multiple myeloma with new novel agents, specifically bortezomib and lenalidomide.
Categories:
Haematology oncology
Related Videos
New classification for identifying HR myeloma based on cytogenetic abnormalities
Dr Jill Corre - IUCT Oncopole, Toulouse, France
29 Oct 2024
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance...
Dr Jill Corre - IUCT Oncopole, Toulouse, France
29 Oct 2024
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new...
Prof Xavier Leleu - CHU de Poitiers, Poitiers, France
28 Oct 2024
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Dr Elias Mai - Heidelberg University, Heidelberg, Germany
28 Oct 2024
Use of bispecifics and CAR T cells in South America
Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
28 Oct 2024
Revolutionising myeloma treatment through immune profiling
Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA
28 Oct 2024
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Prof Joy Ho - The University of Sydney, Sydney, Australia
28 Oct 2024
Guiding transplant decisions in multiple myeloma with MRD
Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA
28 Oct 2024
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA
28 Oct 2024
More from
e
cancer